Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29139788 | 0.91 | TSHR (0.34) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL13897101 | 0.83 | CA14 (0.33) | CA14 | |
| SCHEMBL29890995 | 0.82 | HDAC6 (0.36) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL6580293 | 0.81 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL13897075 | 0.81 | DGAT1 (0.33) | CA14DGAT1CA12CA1CPB2 | |
| SCHEMBL16574588 | 0.80 | CTSS (0.31) | — | |
| SCHEMBL30420929 | 0.78 | CA14 (0.41) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL137000 | 0.78 | HDAC6 (0.46) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL16947002 | 0.77 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL15326145 | 0.77 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396925-B2 | Volatilizable solid phase supports for compound synthesis | MIXTURE SCIENCES, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20060241283-A1 | Volatilizable solid phase supports for compound synthesis | MIXTURE SCIENCES, INC. (US) | 2006-10-26 | — | — | US | disclosed |
| US-7067623-B2 | Volatilizable solid phase supports for compound synthesis | MIXTURE SCIENCES, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1147127-B1 | VOLATILIZABLE SOLID PHASE SUPPORTS FOR COMPOUND SYNTHESIS | MIXTURE SCIENCES INC (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005113573-A2 | METHOD OF SUPPORT-BASED CHEMICAL SYNTHESIS | MIXTURE SCIENCES, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050261474-A1 | Method of support-based chemical synthesis | MIXTURE SCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1147127-A4 | VOLATILIZABLE SOLID PHASE SUPPORTS FOR COMPOUND SYNTHESIS | MIXTURE SCIENCES INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030135024-A1 | Volatilizable solid phase supports for compound synthesis | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES | 2003-07-17 | — | — | US | disclosed |
| EP-1147127-A1 | VOLATILIZABLE SOLID PHASE SUPPORTS FOR COMPOUND SYNTHESIS | Mixture Sciences Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000046238-A1 | VOLATILIZABLE SOLID PHASE SUPPORTS FOR COMPOUND SYNTHESIS | MIXTURE SCIENCES, INC. (US) | 2000-08-10 | — | — | WO | disclosed |
| EP-0558671-B1 | SYNTHESIS OF EQUIMOLAR MULTIPLE OLIGOMER MIXTURES, ESPECIALLY OF OLIGOPEPTIDE MIXTURES | ITEREX PHARMA LP (US) | 1999-01-27 | — | — | EP | disclosed |
| US-5556762-A | Scanning synthetic peptide combinatorial libraries: oligopeptide mixture sets having a one predetermined residue at a single, predetermined position, methods of making and using the same | HOUGHTEN PHARMACEUTICAL INC. (US) | 1996-09-17 | — | — | US | disclosed |
| US-5504190-A | Equimolar multiple oligomer mixtures, especially oligopeptide mixtures | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1996-04-02 | — | — | US | disclosed |
| EP-0558671-A4 | SYNTHESIS OF EQUIMOLAR MULTIPLE OLIGOMER MIXTURES, ESPECIALLY OF OLIGOPEPTIDE MIXTURES | ITEREX PHARMA LP (US) | 1994-05-11 | — | — | EP | disclosed |
| EP-0558671-A1 | SYNTHESIS OF EQUIMOLAR MULTIPLE OLIGOMER MIXTURES, ESPECIALLY OF OLIGOPEPTIDE MIXTURES | ITEREX PHARMACEUTICALS LTD. PARTNERSHIP (US) | 1993-09-08 | — | — | EP | disclosed |
| WO-1992009300-A1 | SYNTHESIS OF EQUIMOLAR MULTIPLE OLIGOMER MIXTURES, ESPECIALLY OF OLIGOPEPTIDE MIXTURES | ITEREX PHARMACEUTICALS LTD. PARTNERSHIP (US) | 1992-06-11 | — | — | WO | disclosed |
| US-4631211-A | REACTIVE PARTICLES ENCLOSED IN WATER AND SOLVENT-INSOLUBLE MESH CONTAINER; PEPTIDE SYNTHESIS | SCRIPPS CLINIC & RESEARCH FOUNDATION (US) | 1986-12-23 | — | — | US | disclosed |
| EP-0196174-A2 | Means for sequential solid phase organic synthesis and methods using the same | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135024-A1 | Volatilizable solid phase supports for compound synthesis | VARS1, SCLY, C9 | HDAC6 3504/4885HDAC1 1691/4885HDAC2 2007/4885 |
| US-20060241283-A1 | Volatilizable solid phase supports for compound synthesis | VARS1, SCLY, C9 | HDAC6 3504/4885HDAC1 1691/4885HDAC2 2007/4885 |
| US-20050261474-A1 | Method of support-based chemical synthesis | CYP2F1, CYP4F3, CYP4F2 | HDAC6 4215/4885HDAC1 3389/4885HDAC2 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.